Research ExplorerPublicationsSilibinin is a potent antiviral agent in patients with chron...

Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy

Standard

Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. / Ferenci, Peter; Scherzer, Thomas-Matthias; Kerschner, Heidrun; Rutter, Karoline; Beinhardt, Sandra; Hofer, Harald; Schöniger-Hekele, Maximilian; Holzmann, Heidemarie; Steindl-Munda, Petra.

In: GASTROENTEROLOGY, Vol. 135, No. 5, 01.11.2008, p. 1561-7.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Ferenci, P, Scherzer, T-M, Kerschner, H, Rutter, K, Beinhardt, S, Hofer, H, Schöniger-Hekele, M, Holzmann, H & Steindl-Munda, P 2008, 'Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy', GASTROENTEROLOGY, vol. 135, no. 5, pp. 1561-7. https://doi.org/10.1053/j.gastro.2008.07.072

APA

Ferenci, P., Scherzer, T-M., Kerschner, H., Rutter, K., Beinhardt, S., Hofer, H., Schöniger-Hekele, M., Holzmann, H., & Steindl-Munda, P. (2008). Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. GASTROENTEROLOGY, 135(5), 1561-7. https://doi.org/10.1053/j.gastro.2008.07.072

Vancouver

Ferenci P, Scherzer T-M, Kerschner H, Rutter K, Beinhardt S, Hofer H et al. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. GASTROENTEROLOGY. 2008 Nov 1;135(5):1561-7. https://doi.org/10.1053/j.gastro.2008.07.072

Bibtex

@article{15abc43c4a4148609891db6837e61ad8,
title = "Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy",
abstract = "BACKGROUND & AIMS: Oral Silibinin (SIL) is widely used for treatment of hepatitis C, but its efficacy is unclear. Substantially higher doses can be administered intravenously (IV).METHODS: Pedigreed nonresponders to full-dose pegylated (Peg)-interferon/ribavirin (PegIFN/RBV) were studied. First, 16 patients received 10 mg/kg/day SIL IV (Legalon Sil; Madaus, K{\"o}ln, Germany) for 7 days. In a subsequent dose-finding study, 20 patients received 5, 10, 15, or 20 mg/kg/day SIL for 14 days. In both protocols, PegIFN alpha-2a/RBV were started on day 8. Viral load was determined daily.RESULTS: Unexpectedly, in the first study, HCV-RNA declined on IV SIL by 1.32 +/- 0.55 log (mean +/- SD), P < .001 but increased again in spite of PegIFN/RBV after the infusion period. The viral load decrease was dose dependent (log drop after 7 days SIL: 0.55 +/- 0.5 [5 mg/kg, n = 3], 1.41 +/- 0.59 [10 mg/kg, n = 19], 2.11 +/- 1.34 [15 mg/kg, n = 5], and 3.02 +/- 1.01 [20 mg/kg, n = 9]; P < .001), decreased further after 7 days combined SIL/PegIFN/RBV (1.63 +/- 0.78 [5 mg/kg, n = 3], 4.16 +/- 1.28 [10 mg/kg, n = 3], 3.69 +/- 1.29 [15 mg/kg, n = 5], and 4.85 +/- 0.89 [20 mg/kg, n = 9]; P < .001), and became undetectable in 7 patients on 15 or 20 mg/kg SIL, at week 12. Beside mild gastrointestinal symptoms, IV SIL monotherapy was well tolerated.CONCLUSIONS: IV SIL is well tolerated and shows a substantial antiviral effect against HCV in nonresponders.",
keywords = "Antioxidants, Antiviral Agents, Dose-Response Relationship, Drug, Drug Carriers, Drug Resistance, Viral, Drug Therapy, Combination, Female, Follow-Up Studies, Free Radical Scavengers, Hepacivirus, Hepatitis C, Chronic, Humans, Infusions, Intravenous, Interferon-alpha, Male, Middle Aged, Milk Thistle, Polyethylene Glycols, Polymerase Chain Reaction, RNA, Viral, Recombinant Proteins, Ribavirin, Silymarin, Time Factors, Treatment Outcome, Viral Load",
author = "Peter Ferenci and Thomas-Matthias Scherzer and Heidrun Kerschner and Karoline Rutter and Sandra Beinhardt and Harald Hofer and Maximilian Sch{\"o}niger-Hekele and Heidemarie Holzmann and Petra Steindl-Munda",
year = "2008",
month = nov,
day = "1",
doi = "10.1053/j.gastro.2008.07.072",
language = "English",
volume = "135",
pages = "1561--7",
journal = "GASTROENTEROLOGY",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "5",

}

RIS

TY - JOUR

T1 - Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy

AU - Ferenci, Peter

AU - Scherzer, Thomas-Matthias

AU - Kerschner, Heidrun

AU - Rutter, Karoline

AU - Beinhardt, Sandra

AU - Hofer, Harald

AU - Schöniger-Hekele, Maximilian

AU - Holzmann, Heidemarie

AU - Steindl-Munda, Petra

PY - 2008/11/1

Y1 - 2008/11/1

N2 - BACKGROUND & AIMS: Oral Silibinin (SIL) is widely used for treatment of hepatitis C, but its efficacy is unclear. Substantially higher doses can be administered intravenously (IV).METHODS: Pedigreed nonresponders to full-dose pegylated (Peg)-interferon/ribavirin (PegIFN/RBV) were studied. First, 16 patients received 10 mg/kg/day SIL IV (Legalon Sil; Madaus, Köln, Germany) for 7 days. In a subsequent dose-finding study, 20 patients received 5, 10, 15, or 20 mg/kg/day SIL for 14 days. In both protocols, PegIFN alpha-2a/RBV were started on day 8. Viral load was determined daily.RESULTS: Unexpectedly, in the first study, HCV-RNA declined on IV SIL by 1.32 +/- 0.55 log (mean +/- SD), P < .001 but increased again in spite of PegIFN/RBV after the infusion period. The viral load decrease was dose dependent (log drop after 7 days SIL: 0.55 +/- 0.5 [5 mg/kg, n = 3], 1.41 +/- 0.59 [10 mg/kg, n = 19], 2.11 +/- 1.34 [15 mg/kg, n = 5], and 3.02 +/- 1.01 [20 mg/kg, n = 9]; P < .001), decreased further after 7 days combined SIL/PegIFN/RBV (1.63 +/- 0.78 [5 mg/kg, n = 3], 4.16 +/- 1.28 [10 mg/kg, n = 3], 3.69 +/- 1.29 [15 mg/kg, n = 5], and 4.85 +/- 0.89 [20 mg/kg, n = 9]; P < .001), and became undetectable in 7 patients on 15 or 20 mg/kg SIL, at week 12. Beside mild gastrointestinal symptoms, IV SIL monotherapy was well tolerated.CONCLUSIONS: IV SIL is well tolerated and shows a substantial antiviral effect against HCV in nonresponders.

AB - BACKGROUND & AIMS: Oral Silibinin (SIL) is widely used for treatment of hepatitis C, but its efficacy is unclear. Substantially higher doses can be administered intravenously (IV).METHODS: Pedigreed nonresponders to full-dose pegylated (Peg)-interferon/ribavirin (PegIFN/RBV) were studied. First, 16 patients received 10 mg/kg/day SIL IV (Legalon Sil; Madaus, Köln, Germany) for 7 days. In a subsequent dose-finding study, 20 patients received 5, 10, 15, or 20 mg/kg/day SIL for 14 days. In both protocols, PegIFN alpha-2a/RBV were started on day 8. Viral load was determined daily.RESULTS: Unexpectedly, in the first study, HCV-RNA declined on IV SIL by 1.32 +/- 0.55 log (mean +/- SD), P < .001 but increased again in spite of PegIFN/RBV after the infusion period. The viral load decrease was dose dependent (log drop after 7 days SIL: 0.55 +/- 0.5 [5 mg/kg, n = 3], 1.41 +/- 0.59 [10 mg/kg, n = 19], 2.11 +/- 1.34 [15 mg/kg, n = 5], and 3.02 +/- 1.01 [20 mg/kg, n = 9]; P < .001), decreased further after 7 days combined SIL/PegIFN/RBV (1.63 +/- 0.78 [5 mg/kg, n = 3], 4.16 +/- 1.28 [10 mg/kg, n = 3], 3.69 +/- 1.29 [15 mg/kg, n = 5], and 4.85 +/- 0.89 [20 mg/kg, n = 9]; P < .001), and became undetectable in 7 patients on 15 or 20 mg/kg SIL, at week 12. Beside mild gastrointestinal symptoms, IV SIL monotherapy was well tolerated.CONCLUSIONS: IV SIL is well tolerated and shows a substantial antiviral effect against HCV in nonresponders.

KW - Antioxidants

KW - Antiviral Agents

KW - Dose-Response Relationship, Drug

KW - Drug Carriers

KW - Drug Resistance, Viral

KW - Drug Therapy, Combination

KW - Female

KW - Follow-Up Studies

KW - Free Radical Scavengers

KW - Hepacivirus

KW - Hepatitis C, Chronic

KW - Humans

KW - Infusions, Intravenous

KW - Interferon-alpha

KW - Male

KW - Middle Aged

KW - Milk Thistle

KW - Polyethylene Glycols

KW - Polymerase Chain Reaction

KW - RNA, Viral

KW - Recombinant Proteins

KW - Ribavirin

KW - Silymarin

KW - Time Factors

KW - Treatment Outcome

KW - Viral Load

U2 - 10.1053/j.gastro.2008.07.072

DO - 10.1053/j.gastro.2008.07.072

M3 - SCORING: Journal article

C2 - 18771667

VL - 135

SP - 1561

EP - 1567

JO - GASTROENTEROLOGY

JF - GASTROENTEROLOGY

SN - 0016-5085

IS - 5

ER -